Long-acting β2-agonists in asthma: An overview of Cochrane systematic reviews

31Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

According to major asthma management guidelines, long-acting β2-agonists (LABAs) should be used only when asthma remains symptomatic in patients already receiving regular inhaled corticosteroids (ICSs). A large Cochrane systematic review provides evidence that LABAs are safe and beneficial in control of asthma; sub-group analyses indicating that this is true when ICSs are used and in their absence. Two other Cochrane systematic reviews have found that LABAs are more effective than regular short-acting β2 -agonists, and are as effective as theophylline with fewer side-effects. These reviews support guidelines in the use of LABA as additional therapy when asthma is inadequately controlled by ICS at moderate dose. However, guidelines may be too conservative, and more studies in stable mild asthma comparing their use and safety with placebo and ICS are required. © 2005 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Walters, J. A. E., Wood-Baker, R., & Walters, E. H. (2005). Long-acting β2-agonists in asthma: An overview of Cochrane systematic reviews. Respiratory Medicine, 99(4), 384–395. https://doi.org/10.1016/j.rmed.2005.01.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free